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Future Perspectives 
The use of pseudotyped viruses has historically been limited to a small number of readily 
tractable viruses. However, the flexibility of pseudotyped viruses makes them attractive 
as safe surrogates for enveloped viruses requiring high bio-containment, for use in 
serological screening, assessing vaccine efficacy, targeted gene transduction, virus entry 
inhibition and receptor usage studies. Through the development of more standardized 
protocols, a broader range of reporter genes and backbone viruses, virus pseudotyping 
will become a central and powerful technique in the study and treatment of enveloped 
viruses. 
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Executive Summary 
A pseudotyped virus (PV) is a virus particle with an envelope protein originating from a 
different virus. The ability to dictate which envelope proteins are expressed on the 
surface has made pseudotyping an important tool for basic virological studies such as 
determining the cellular targets of the envelope protein as well as identification of 
potential antiviral compounds and measuring specific antibody responses. In this review, 
we describe the common methodologies employed to generate pseudotyped viruses 
(PVs) with a focus on approaches to improve the efficacy of PV generation. 
What are pseudotyped viruses? 
In 1911, Peyton Rous published the first report of a non-cellular, filterable agent that 
could produce cancer - a sarcoma of chickens [1]. This agent was later named the Rous 
sarcoma virus (RSV) and was used to generate the first virus pseudotypes [2].  
 
Rubin and colleagues [3] discovered that infectious RSV particles were not released from 
sarcoma cells during infection with RSV alone. However, if RSV-transformed sarcoma 
cells were co-infected with a helper avian leukosis virus, Rous-associated virus (RAV), 
then infectious RSV and RAV progeny were released (as RSV and RAV are antigenically-
unrelated avian C-type retroviruses they could be distinguished). Importantly, it was 
also shown that the RSV particles produced possessed the RSV genome but the RAV 
RXWHUµFRDW¶DVGHWHUPLQHGE\VHURORJ\DQGFHOOWURSLVP[2, 3]. They called these hybrid 
SDUWLFOHVµSVHXGRW\SHV¶ 
 
A serendipitous property of retroviruses such as RSV is their natural ability to 
incorporate other cellular proteins, including the envelope proteins of other viruses [4-
6]. The discovery that human immunodeficiency virus 1 (referred to as HIV in this 
review) effectively incorporates the envelope proteins from human T-lymphotrophic virus 
1 (HTLV-1) [4] provided evidence that this virus is a tractable platform for making 
  
3 
 
recombinant PVs. Murine leukemia virus (MLV, also referred to as MuLV or Moloney 
murine leukemia virus, MoMLV) was independently discovered to assemble infectious 
particles with HTLV-1 envelope proteins [7].  
 
Nomenclature has developed alongside molecular knowledge. The protein nucleocapsid 
HQFDVLQJWKHULERQXFOHLFDFLG51$JHQRPHLVQRZNQRZQDVWKHµFRUH¶DQGWKHRXWHU
membrane of these virus particles, derived from the host cell membrane during viral 
HJUHVVE\µEXGGLQJ¶DVDQµHQYHORSH¶7KXVSURWHLQVHPEHGGHGLQWKHPHPEUDne become 
incorporated in the viral envelope and define particle antigenicity and cell tropism.  Here, 
WKHWHUPµSVHXGRW\SHGYLUXV¶39LVGHILQHGDVDQHQYHORSHGYLUXVSDUWLFOHFRPSULVLQJD
virus capsid/matrix/core surrounded by a cell-derived membrane bearing the foreign 
virus envelope protein(s) (VEP). The genetic material packaged by a PV does not encode 
a VEP. Therefore, a PV is capable only of entering and transducing a target cell, initiating 
nucleic acid replication without producing infectious particles. Depending upon end-user 
application, PVs have been variously referred to as pseudotypes, pseudo-viruses, 
pseudo-particles, virus pseudotypes, lenti- or retrovirus vectors, trans-complemented 
viruses, gene transfer vectors, reporter virus particles and virus-like particles. It is 
important to note that many of these terms have also been used to describe particles or 
WHFKQLTXHVWKDWGRQRWILWWKHDERYHGHILQLWLRQ7KHWHUPµYLUXVHQYHORSHSURWHLQ¶ is used 
UDWKHUWKDQµYLUXVJO\FRSURWHLQV¶WRLQFOXGHnon-glycosylated viral surface proteins such 
as the mature form of the flavivirus M protein and exclude glycosylated non-structural 
SURWHLQV)XUWKHUPRUHWKHGLVWLQFWLRQEHWZHHQ9(3DQGµYLUXVVXUIDFHSURWHLQ¶
distinguishes PVs from techniques involving non-enveloped viruses (e.g. adeno-
associated virus vectors). 
 
$IXQFWLRQDO39FDQEHJHQHUDWHGE\WUDQVIHFWLRQRIDµSURGXFHU¶FHOOZLWKWKUHHSODVPLGV
(Figure 1).  7KH39µEDFNERQH¶LVDYLUXVWKDWSURYLGHVERWKWKHFRUHDQGWKHUHFRPELQDQW
genome packaged by PVs. This combination is essential because genome packaging is 
mediated by specific interactions between sequences in the genome and the 
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core/matrix/capsid. The most commonly used PV backbones are HIV or MLV retroviruses 
for which the core expression plasmid encodes the gag and pol genes with no packaging 
signal. The recombinant genome is typically a reporter gene such as luciferase flanked 
by retroviral long terminal repeats (LTRs) and DSDFNDJLQJVLJQDOǓ. The third plasmid 
expresses the open reading frame of the VEP of the virus of interest with appropriate 
signal peptide.  
Applications of pseudotyped viruses (PVs) 
The flexibility of PVs means that they are suitable for a wide range of applications. A key 
feature of PVs is that they cannot replicate apart from the reporter gene maintained as 
the genome; they are therefore widely used at ACDP/BSL 1 or 2 (regardless of the origin 
of the VEP) and have been particularly valuable in the study of highly pathogenic 
viruses. 
 
PVs for research and therapeutic agent screening 
PVs offer the ability to rapidly generate key data in the characterization of virus±host 
interactions. The use of PVs has been of crucial significance in the rapid pace of research 
into the Middle Eastern Respiratory syndrome (MERS) outbreak [8-11]. During the 
recent Ebola outbreak, PVs were successfully used in high-throughput screening studies 
that helped in the identification of potential antivirals and filovirus entry inhibitors [12-
14] as well as in the study of the viral life cycle and virus receptor interaction [15].  
 
PVs have been used extensively to investigate the entry cascade of hepatitis C virus 
(HCV) for which, until recently, a robust in vitro cell-culture system did not exist for 
primary virus isolates. The two glycoproteins of HCV, E1 and E2, have been successfully 
expressed and incorporated into PVs, initially as modified glycoproteins into VSV 
backbones [16], then later as unmodified constructs using VSV [17], MLV [6] and HIV 
[18] backbones. The entry pathway of genetically diverse HCV strains was dissected 
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using these experimental systems, revealing a requirement for an array of receptors 
[19-23]. Both E1 and E2 are required for assembly of infectious PVs with E2 acting as a 
chaperone for E1 incorporation, interacting with both E1 and the retroviral core [24]. 
Using PVs to investigate the effects of specific point mutations on HCV entry also 
revealed key amino acids involved in receptor interactions [25-27]. However, 
comparison with authentic HCV viruses revealed that PVs are less tolerant to alteration 
in vitro.  
PVs for measuring antibodies 
PVs have been used as surrogates of wild-type viruses in sensitive, high throughput 
neutralization assays (PVNAs), also referred to as pseudotyped particle- (pp-) or 
pseudotyped virus-based microneutralization assays (pv-MN). For most PVNAs, serial 
dilutions of sera are incubated with a pre-determined amount of a PV (quantified by the 
measurement of reporter gene expression) for one hour at 37°C. A fixed amount of 
virus-susceptible target cells is then added and reporter gene expression measured after 
an appropriate incubation period (e.g. 48 hours) [28]. The titer of antibody is typically 
expressed as the highest dilution of the sample that reduces reporter gene expression by 
either 50% (IC50) or 90% (IC90) compared to controls [29]. The PVNA is typically 
sample-sparing. The option to incorporate a number of different reporter genes means 
that PVs can be adapted to a multiplex serum screening format [30, 31].  
 
Comparative serology studies for highly pathogenic avian influenza (HPAI) of the H5 
subtype have shown that results from more traditional serological assays including 
hemagglutination inhibition, micro-neutralization and single radial hemolysis correlate 
well with those obtained by PVNA [32]. It is thought that a lower density of 
hemagglutinin (HA) on the surface of influenza PVs compared to wild-type virus means 
that a sub-set of antibodies are better able to access cross-reactive epitopes on the stalk 
of the VEP. The PVNA can therefore be used to measure antibodies generated by 
SURWRW\SHµXQLYHUVDOYDFFLQHV¶FRPSRVHGRI+$VWHPIUDJPHQWV7KHVHDQWLERGLHVFDQQRW
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be measured by the classical hemagglutination inhibition test as this relies on measuring 
blocking of antibodies against the receptor-binding site on the globular head of the HA, 
which is missing [33, 34].  
 
PVs have also been widely used to investigate neutralization of HCV entry. The PVNA was 
first established to test the neutralizing potency of sera [35-37] and monoclonal 
antibodies [38-42] against diverse strains of HCV. This revealed the existence of 
broadly-neutralizing antibodies generated during natural infection [43, 44] and following 
immunization with vaccines [45, 46]. Studies using PVs demonstrated that serum 
contains factors other than antibodies that have the potential to neutralize HCV entry 
[47-49], while the apolipoprotein components  of serum can enhance HCV infectivity and 
protect against antibody-mediated neutralization [50, 51]. Direct comparison of HCV PVs 
and wild-type HCV viruses revealed that PVs are more resistant to antibody-mediated 
neutralisation [41], suggesting that PVNA might over-estimate the amounts of antibody 
required for clinical administration.  
 
Retroviral PVs bearing the HIV-1 glycoproteins have also been used for high throughput 
PVNA and assessment of vaccine-induced immunity. Comparison of an array of different 
assays in multiple laboratories found that PVs were generally more sensitive to 
neutralization than replicating viruses [52, 53], confirming previous findings [54]. As 
such, PVs might not accurately determine the neutralization potency of inhibitors against 
a single virus strain, but provide a powerful and rapid method for comparing the 
neutralization sensitivity of many different strains.  
PVs as vaccines 
The production of neutralizing antibodies is a hallmark of successful vaccination resulting 
in protection against virus infections (reviewed in [55]). As VEPs are the key targets of 
neutralizing antibodies, PVs capable of expressing different proteins might be a very 
useful platform for vaccine design. Indeed, immunization with VSV-based PVs has been 
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shown to protect mice against challenge with influenza [56]. However, disadvantages 
include the potential risk of genomic integration (see below) and lack of sustained 
antigen production, and greater efforts have been made to develop virus-like particle 
(VLP)-based vaccines (reviewed in [57]).  
PVs for gene transfer 
The comparative ease with which VEPs can be swapped has been exploited to produce 
retrovirus delivery vectors for gene transfer where the integration of packaged transgene 
into the target cell genome enables longer-term gene expression compared with the 
episomal vectors, typified by many DNA viruses. The first gene therapy vectors were 
based on retroviruses with their gag, pol and env regions removed and replaced with a 
therapeutic gene and sometimes a selective marker. During vector production, the gag, 
pol and env protein products were supplied in trans by suitable stable packaging cell 
lines. Although the first gene therapy trial employed a retrovirus vector with its cognate 
envelope protein [58], soon after, heterologous retrovirus envelopes were used, 
primarily to enhance target cell transduction and thus therapeutic gene expression [59].  
One issue with the original C-type retrovirus vectors (e.g. MLV) was that they were only 
able to transduce dividing cells. To address this issue, researchers turned to the 
lentiviruses (e.g. HIV), which do not require replicating cells for efficient transduction. 
 
Another issue has been that of insertional mutagenesis as a result of genomic integration 
of the transfer gene causing activation of oncogenes [60]. Though a rare occurrence, it 
did manifest itself by producing leukemia in five patients several years after gene 
therapy for severe combined immunodeficiency [61]. It is believed that the viral control 
elements situated in the retrovirus LTRs activate host genes. Consequently, self-
inactivating vectors have been designed which eliminate these elements [62]. 
In order to alter the natural cell tropism of transfer vectors, heterologous envelope 
glycoproteins have been employed with varying degrees of success [63]. VSV-G was 
used for pseudotyping retrovirus vectors [64] to broaden the range of target cells, 
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tissues and species, and has been widely adopted since. Conversely, pseudotyping 
provides the means to retarget viral vectors for transduction of particular targets, such 
as lung, central nervous system, kidney, liver and hematopoietic cells [63]. 
Considerations for developing novel pseudotyped viruses 
Many different viruses have been pseudotyped. However there is no single standardized 
experimental approach. There are many factors that need to be considered when 
generating a novel virus pseudotype, taking into account numerous aspects of the virus 
biology, the intended application and how tractable the virus is to forming PVs. These 
are expanded upon in the following sections and summarized in Figure 2. 
The "plug and play" pseudotype construction model is exemplified by influenza PVs 
assembled using retroviral cores. With a toolkit of 6 plasmids and a streamlined 
optimization grid for transfection, most strains of influenza are currently amenable to 
pseudotyping onto retroviral cores [65-67]. Essentially these assembly processes fall 
broadly into three protocols with the one chosen being dependent on the HA to be 
pseudotyped and also the downstream application. The simplest system is employed for 
generating PVs from highly pathogenic avian influenza viruses of the H5 and H7 
subtypes which possess multi-basic HA cleavage sites. These are ideal when only HA-
mediated cell entry is required as there will be no neuraminidase (NA) on the released 
PVs [68, 69]. Inclusion of a plasmid encoding NA generates particles that more closely 
mimic their cognate wild-type virus, which is useful for surveillance and vaccine 
immunogenicity studies (whole virus vaccines). In order to effectively pseudotype HAs 
that possess a monobasic HA cleavage site (e.g. from seasonal human influenza 
viruses), a protease must be supplied (as described below).  
 
Viral backbones for pseudotyping  
As previously mentioned, HIV or MLV retroviruses are the most commonly used 
backbones for PV production. The HIV backbone for PVs has undergone several iterations 
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to improve safety including the deletion of accessory proteins, promoter sequences and 
the provision of the HIV rev gene on a separate fourth plasmid (reviewed in [70]). 
Systems are also available whereby the reporter gene is encoded on the gag-pol plasmid 
reducing it to a two plasmid transfection system. When establishing a novel virus PV 
system it may be relevant to consider which generation of HIV backbone to use as it has 
been reported that nef co-expression enhanced PV assembly of VEPs from retroviruses, 
but not non-retroviruses, on the HIV backbone [71]. Two and three plasmid systems, 
comparable to the lentivirus system, exist for MLV. MLV is non-pathogenic in humans 
and has fewer accessory proteins compared to HIV. It was the preferred PV backbone 
prior to development of the second and third generation HIV systems but the two 
retrovirus backbones are now comparable in terms of safety and ease of use. 
 
Not all VEPs are incorporated efficiently into HIV or MLV backbones [72]; the choice of 
backbone for pseudotyping a novel virus may be informed by reports of successful 
systems published for related viruses.  The vesicular stomatitis virus (VSV) system, 
which was originally applied to the study of Ebola virus (EBOV) envelope proteins [73], 
provides an alternative. VSV is a single-stranded negative sense RNA virus encoding 5 
genes that are transcribed on separate mRNAs, enabling deletion or substitution of any 
given gene for a heterologous gene. PVs can be generated by combining a recombinant 
VSV genome, in which the VSV-G gene has been deleted (rVSV-ǻG*) and is replaced 
with a reporter gene, with an expression plasmid encoding the desired VEP(s).  
 
Establishment of the rVSV-ǻG* system is complex (Figure 3). In order to initiate 
replication of the rVSV-ǻG* genome, cells must be transfected with the pVSV-ǻG* 
genome plasmid and plasmids expressing the VSV nucleoprotein (N), phosphoprotein (P) 
and polymerase protein (L). Furthermore, initial transcription of the VSV-ǻG* genome 
from the plasmid is controlled by the T7 RNA polymerase promoter (T7 pol). T7 pol is 
commonly provided by one of two methods: infection of the producer cells with a 
recombinant virus expressing T7 pol (modified vaccinia virus Ankara (MVA)-T7 or 
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fowlpox virus (FPV)-T7) or by using a clone of the BHK-21 cell line stably expressing T7 
pol from a plasmid [74]. T7 helper viruses are preferred because they achieve higher 
levels of T7 pol activity compared to stable cell lines. The addition of a VSV-G expression 
plasmid results in the production of particles encapsidating the VSV-ǻG* genome and 
coated with VSV-G, or VSV-pseudotyped rVSV. Infection of target cells (lacking the T7 
pol and the VSV accessory protein expression plasmids) with these PVs leads to efficient 
replication of the VSV-ǻG* genome and production of non-infectious ǻEnv-rVSV. 
Therefore transfection of cells with a heterologous VEP expression plasmid and 
subsequent infection with VSV-pseudotyped rVSV particles leads to the production of 
heterologous VEP-pseudotyped rVSV. However, due to the high efficiency of VSV-G 
pseudotyping, it is important to assess PV neutralization with antibodies against the 
heterologous virus envelope and VSV-G to confirm the composition of the PVs. A 
comprehensive method for the production of VSV-based PVs is given in [75].  
Provision of proteases 
Many viruses make use of host cell proteases for the production or release of mature 
virus particles. Furthermore, protease usage can be a critical determinant of viral 
tropism [76]. For seasonal human influenza viruses, the requirement for protease-
mediated cleavage of the hemagglutinin in order for it to become fusion competent is a 
well-documented trait [65, 77-79]. However, protease activation is also a well-studied 
component in the Paramyxoviridae (a family of negative sense single-strand RNA 
viruses), where the F protein precursor must be cleaved in order to facilitate maturation 
of the fusion protein [80], and in the Coronaviridae (a family of positive sense, single-
strand RNA viruses) where proteases can be involved in both cleavage of the spike 
protein and facilitating release from the host cell [81-83].  Therefore, it may be 
necessary to supplement PV generation protocols with specific proteases. In many 
studies it has become common practice to co-transfect a protease-encoding plasmid 
alongside the other plasmids required for PV production [65, 77, 79, 84]. For influenza, 
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the most commonly used proteases when supplied as a plasmid are HAT and TMPRSS2 
[77].   
 
It is also possible to induce protease-mediated activation through the addition of purified 
protease to the culture medium or purified PV preparation. The addition of exogenous 
tosyl phenylalanyl chloromethyl ketone (TPCK) trypsin has been demonstrated to 
facilitate activation of SARS-CoV [85, 86] MERS-CoV [10, 87] and human coronavirus 
229E [88]. Exogenous TPCK trypsin is also used for influenza, but an additional step is 
required in order to deactivate the protease, using commercially available protease 
inhibitors, prior to inoculation of the PVs onto target cells [65, 77]. 
 
Signal peptides and transmembrane domains 
Appropriate signal peptides (SPs) and transmembrane domains (TMDs) are a key 
component of successful PV production as they contribute to sub-cellular targeting and 
membrane retention of the VEP. It is necessary to target VEPs to the endoplasmic 
reticulum to facilitate trafficking to sites of assembly. The exact site of retrovirus 
budding is yet to be completely defined. The cytoplasmic tails of VEPs have also been 
identified as important factors [89-91]. Gibbon ape leukemia virus (GaLV) required the 
cytoplasmic domains of MLV glycoproteins to form PVs on an HIV-1 backbone [92]. 
 
VEP alteration 
The diverse structure of VEPs, a characteristic used to divide them into three major 
classes (I±III), can be the cause of their inefficient incorporation into PVs and 
consequently poor viral titers. Issues such as localization to the Golgi complex may be 
overcome by splicing together different sections of heterologous VEPs, to generate 
chimeric proteins. The structure of a VEP can be crudely broken down into the ecto-, 
transmembrane and cytoplasmic domains. Ectodomains play the major role in cell 
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binding and antigenicity so any alterations could affect serological and tropism properties 
of the VEP so this domain should usually be maintained. However, several studies have 
shown that switching of the cytoplasmic domains is one mechanism by which PV titers 
can be improved [16, 93, 94]. Carpentier et al. conducted a detailed series of 
experiments to determine if titers of lentiviral PV bearing the rabies virus envelope 
protein (RABV-G) could be improved by engineering chimeric VEPs [94]. By swapping in 
the corresponding domains from VSV-G they were able to generate a series of chimeric 
VEPs and determine efficiency of VEP incorporation into PVs and infectivity. The only 
chimera that led to an increase in PV titer comprised the RABV-G ecto- and 
transmembrane domains with the VSV-G cytoplasmic domain. This work has been 
expanded by Bentley et al. who showed that RABV-G which previously gave no or very 
low/unusable PV titers could successfully be pseudotyped by swapping the cytoplasmic 
domain for that of VSV-G [95]. However, it is important to note that there is some 
variation within the literature about the exact sequence for the VSV cytoplasmic domain 
[16, 96, 97]. 
 
The reason chimeric VEPs result in better incorporation of VEP and higher PV titer is 
unclear. It could be due to a stronger interaction with the backbone matrix/capsid 
protein if the cytoplasmic domain being introduced is shorter as this may reduce steric 
hindrance. Alternatively, the chimeric VEPs may be trafficked more efficiently to the sites 
from which the backbone virus naturally buds. 
 
Other modifications to VEPs can boost titers. Measles virus has two envelope proteins, F 
and H, and it has been shown that if the full-length wild-type VEPs are used then only 
very small quantities of infectious PV are produced [98]. However, if both VEPs are 
truncated, H'24 and F'30, levels of incorporation into PV and the PV titer are both 
markedly higher. 
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Optimizing PV titers 
The VSV glycoprotein (VSV-G) produces high titer PVs and is therefore commonly used 
as a positive control in developing novel PVs. Hepatitis B virus represents the other 
extreme where existing systems result in very low infectious PV titers [99]. 
Quantification of PVs obtained 
PV titer is most commonly determined by measuring reporter gene expression in 
susceptible target cell lines. However, if little or no expression is seen, it may be 
necessary to conduct further tests. For retrovirus-based PVs this appears to 
underestimate the number of cells that have undergone genome integration, due to 
variability of marker expression; PCR has been employed to determine this more 
precisely [100, 101]. Titration of viral genomic RNA from producer line supernatants 
conversely overestimates the number of infectious particles due to the presence of 
defective interfering particles. Titration of HIV-based PV preparations can also be 
performed by Gag (p24) protein ELISA [102] with infectivity defined as number of 
infectious units per unit of p24. Lastly, titration of several retroviral vectors based on 
reverse transcriptase activity via qPCR has recently been reported [103]. 
 
Virus particle analysis has historically been conducted via electron microscopy. However, 
new technologies (e.g. nanoparticle tracking analysis) have enabled rapid quantification 
of virus particles and determination of particle size [104]. The continued development of 
such systems may provide vital information on the efficacy of PV production, both in 
terms of quantity and quality. 
 
If low titers of PV production are demonstrated, there are several measures that can be 
taken to boost these to more usable levels as described below. On the other hand, if no 
detectable titers are observed, it may be necessary to change the approach (for example 
using a different backbone or generating a chimeric VEP).  
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Concentration of PVs  
Ultracentrifugation combined with a sucrose cushion or gradient can be used to 
concentrate PVs [18, 105]. Concentration of PVs can also be performed using 
polyethylene glycol (PEG)-precipitation. PEG precipitation has advantages over 
ultracentrifugation, which requires expensive equipment, and low speed centrifugation, 
which can be time consuming. Optimization of incubation time and molecular weight and 
concentration of PEG used will all be required, however numerous commercial kits are 
available with specific protocols. An optimized method for MLV uses 8.5% (w/v) PEG 
6000 for 90 minutes at 4°C followed by collection of the precipitate by centrifugation at 
7,000 x g for 10 minutes [106, 107]. 
 
Influence of plasmid and codon optimization 
Codon optimization is used to increase the expression of a protein in organisms by 
increasing translational efficiency. Most amino acids are encoded by more than one 
codon with each codon recognized by a specific tRNA. Organisms have developed 
LQGLYLGXDOSUHIHUHQFHVIRUSDUWLFXODUFRGRQVIRUDJLYHQDPLQRDFLGNQRZQDVµFRGRQ
XVDJHELDV¶$VWKHHIILFLHQWJHQHUDWLRQRI39VUHTXLUHVJRRGOHYHOVRI9(3H[SUHVVion in 
the producer cells, codon optimization relevant for the given producer cell line may 
improve viral titers [108-111].  
 
The plasmids used to encode the VEP(s) can also greatly influence expression levels and 
therefore PV titer [112, 113]. In order to maximize the level of VEP expression, plasmids 
with strong promotor elements are used such as pcDNA, pCAGGS or phCMV. Expression 
in these plasmids is driven by either the human cytomegalovirus major immediate early 
or beta-actin promotor, two of the strongest promotors that have been identified. As 
pcDNA- and phCMV-based plasmids are commercially available they negate downstream 
intellectual property conflicts. 
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The methods of producing PVs on both the VSV and retroviral backbones involve 
transfection of producer cells with multiple plasmids. Establishing successful transfection 
of plasmids in appropriate ratios appears to be important for successful generation of 
infectious PVs. Experiments with HIV-based PVs demonstrated that differences in 
infectivity occur with different amounts of the VEP plasmid [114]. This also occurs for 
MLV-based PVs, with the amount of VEP plasmid being finely tuned to the species of 
virus being pseudotyped [115].  Interestingly, maximal expression of VEP did not always 
correlate with maximal infectivity, suggesting that optimization of the ratio of expression 
of viral capsid genes to VEP might be important to generating infectious particles. 
Use of PV packaging cell lines 
Cell lines stably expressing one or more components of the PV system have been 
developed to standardize and simplify PV production and reduce transfection costs.  
 
Transfecting cells with a plasmid encoding a lentivirus or retrovirus backbone with 
functional LTRs but with a deletion for the packaging signal (ȥ) [116] UHVXOWVLQµ39
SDFNDJLQJFHOOV¶WKDWFRQWLQXDOO\H[SUHVVKLJKOHYHOVRIWKHFDSVLGDQGHQ]\PHVUHTXLUHG
for retrovirus-based PV production. Subsequent transfection of these cells with plasmids 
encoding a VEP gene and a reporter gene, with ȥ signal and LTRs, results in the 
production of functional PVs. Specific packaging cell lines have also been generated by 
maintaining episomal replication of a plasmid encoding the backbone gag-pol genes 
using selection markers [117]. Packaging cell lines have been produced for a range of PV 
backbones, including HIV, MLV and FeLV, and are available commercially. More recently, 
a lentivirus packaging cell line was developed specifically to meet clinical approval 
standards for the generation of PVs for gene therapy by inserting the HIV gag-pol genes 
into the genome of 293FT cells using Cre recombinase mediated cassette exchange 
(RMCE) [118].  
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It is well known that VSV-pseudotyped retrovirus PVs result in high levels of reporter 
gene expression in producer cells due to transduction of the reporter gene at multiple 
sites in the genome [119]. Therefore, transduction of producer cells with VSV-
pseudotyped retrovirus PVs packaging the gene encoding the VEP(s) for a novel virus will 
generate a cell line with potentially high levels of VEP expression. This may be 
appropriate for novel PV candidate viruses with poor envelope protein expression levels. 
 
Improved interaction of PVs with target cells 
During development of entry models for HCV, large differences in PV transduction of 
target cells were observed  [19, 114, 120], in particular PVs representing HCV genotype 
3 were associated with lower infectivity ([19]; unpublished results). As a result, some 
PHWKRGRORJLHVKDYHXVHGSRO\EUHQHRUµVSLQRFXODWLRQ¶WRLQFUHDVHREVHUYHGLQIHFWLYLW\
[114, 121].  
 
As a result of their amino acid composition, VEPs are negatively charged. This can limit 
the initial and sometimes non-specific interaction between the VEP and molecules on the 
target cell surface [122]. Addition of polybrene (hexadimethrine bromide), a cationic 
SRO\PHUWRWKHFHOOFXOWXUHPHGLDW\SLFDOO\DWDILQDOFRQFHQWUDWLRQRIǋJPOLVWKRXJKW
to reduce the charge repulsion between the negatively charged VEPs and receptors such 
as sialic acid or increasing virus aggregation [123]. Spinoculation involves centrifuging 
VPs onto the target cell surface. Both methods have the effect of increasing observed 
signal, but increase the complexity of the downstream applications. 
Conclusions 
The generation of PVs has facilitated progress in research involving highly pathogenic 
viruses and has been beneficial to research involving viruses for which in vitro culture 
methods have not been available. Despite the many success stories, pseudotyping of 
members of some virus families (e.g. the Flaviviridae) has yet to become a routine 
  
17 
 
procedure. Even within virus families for which PVs have been successfully generated, 
not all subtypes of strains can be predictably pseudotyped by the same methods. In 
summary, there are numerous factors to be taken into consideration when generating 
PVs. As the field develops, the range of choice of viral backbones and reporter genes is 
expanding and progress is being made towards the standardization of protocols for 
consistency, which is essential for some of the main applications of PVs. Novel viruses 
may pose technical barriers to pseudotyping, but the resultant PVs will provide a 
powerful tool to dissect aspects of virus binding and entry as well as in the development 
of antivirals and vaccines. 
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Figure legends 
Figure 1. Schematic of the basic three-plasmid approach to generation of a pseudotyped 
virus with a retroviral core. 
 
Figure 2. Summary diagram of factors to consider when generating a pseudotyped virus 
expressing a novel viral envelope protein. 
 
Figure 3. Schematic of generation of a pseudotyped virus with a vesicular stomatitis 
virus (VSV) core.  
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